Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Preferred Stock Liabilities (2019 - 2020)

Harmony Biosciences Holdings' Preferred Stock Liabilities history spans 2 years, with the latest figure at $434.0 million for Q2 2020.

  • For Q2 2020, Preferred Stock Liabilities changed N/A year-over-year to $434.0 million; the TTM value through Jun 2020 reached $434.0 million, changed N/A, while the annual FY2019 figure was $411.3 million, N/A changed from the prior year.
  • Preferred Stock Liabilities for Q2 2020 was $434.0 million at Harmony Biosciences Holdings, up from $411.3 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $434.0 million in Q2 2020 and bottomed at $400.9 million in Q3 2019.